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TNBC defined by a lack of ER, PgR and Her 2 expression in tumor cells occurs most
frequently in young or pre-menopausal women and often have a worst outcome than
patients with other breast cancer subtype. Recent studies have suggested a link between
BRCA mutations and TNBC. BRCA1 and BRCA2 mutations are present in 8-14% and
5% of TNBC unselected for family history of breast cancer respectively. Recent
advances in DNA sequencing have led to the development of breast cancer
susceptibility genes panel to germline genetic testing of patients. We assessed the
frequency of mutations in predisposition gene (BRCA1 -2) and in 7 predictor genes
(BARD1, PALB2, BRIP1, CDH1, PTEN, CH£CK2 and TP53) and the clinical outcome
in a cohort of patients with TNBC unselected for family history of breast and ovarian
cancer in order to evaluate the clinical utility of germline testing in these subset of
TNBC. 36/140 frozen samples of TNBC from patients unselected for family history of
BC and OC were enrolled and germline DNAwas sequenced to identify mutations.
Mutations were identified in 13/36 pts (36.1%), of these 7 (19.5%) in BRCA1 and
BRCA2 genes. Mutations in other predisposition genes were detected in 7/36 pts, with
the majority observed in genes involved in homologous recombination including
PALB2 3/36 (8.3%), BARD1 2/36 5.6%), CDH! 1/36 (2.8%), BRIP1 1/36 (2.8%)
associated with BRCA1 mutation, no mutations were discovered in PTEN and CHEK2.
Pts with TNBC and germline mutations treated with adjuvant/neoadjuvant
chemotherapy have a better outcome in term of DFS and OS than pts with TNBC
without germline mutations, only 4/13 pts with mutation experienced progressive
disease. Due to the restricted number of pts of our cohort is not possible to generalized
our results but we can suggest that germline genetic testing BRCA1 and BRCA2 in
TNBC unselected for family history of BC and OC should be considered. Although
Mutations in other predisposition genes have been observed among patients with
TNBC more data from large trials are needed before to translate the use of these genes
in clinical practice.
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